Phase 3 Oesophageal Cancer Trial, Recruiting NCT07217704 Sponsor: SOFIE Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 3 Oesophageal Cancer Trial, Recruiting

NCT07217704
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older (male or female)
  • You have been diagnosed with stomach cancer, esophageal cancer, or cancer at the junction of the stomach and esophagus, and are currently being assessed to plan your treatment
  • You are reasonably active and able to care for yourself, with only limited restrictions on physical activity (confirm with trial site)
  • You are willing and able to sign a consent form before any study procedures begin
  • You have had, or are scheduled to have, a contrast-enhanced CT scan of your chest, stomach area, and pelvis within 21 days before or after receiving the study imaging agent
  • If you are a woman who could become pregnant, you must agree to use a highly effective form of birth control during the trial (such as hormonal implants, combined contraceptive pills, or having a vasectomized partner)

Who may not be able to join:

  • Your cancer has clearly already spread to other parts of the body in a way that rules out surgery as a treatment option
  • You have a known allergy or sensitivity to the study imaging agent [¹⁸F]FAPI-74
  • You have taken part in another clinical trial involving an experimental drug or diagnostic product within the last 30 days
  • You have received a radioactive medical treatment or imaging agent recently and it has not been long enough since your last dose (confirm with trial site)
  • You have had a previous cancer diagnosis, unless it was a minor skin cancer or early-stage cervical/uterine cancer — or unless you were treated with the intention of curing it and have been cancer-free for more than 5 years
  • Your liver is not functioning well enough, based on specific blood test results (confirm with trial site)
  • Your kidneys are not functioning well enough, based on a specific measure of kidney filtration (confirm with trial site)
  • You are currently pregnant or breastfeeding — a pregnancy test will be required if there is any chance you could be pregnant
  • You are unable to lie still or complete the PET/CT scan procedure
  • You have inflammatory bowel disease, such as Crohn's disease or ulcerative colitis
  • You have a condition called sarcoidosis
  • You have already started treatment (such as chemotherapy, radiation, immunotherapy, or surgery) aimed at curing your stomach or esophageal cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sherly Mosessian, Ph.D, SOFIE

Phone: 1-800-753-5368

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
SOFIE
Registry
ClinicalTrials.gov
Start date
14 November 2025
Est. completion
30 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Sensitivity and specificity for detection of distant metastatic disease (M1) using a composite SOT as reference

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov